The Value of Botox-A for Management of Low Anterior Resection Syndrome

Rectal Cancer Clinical Trial

Official title:

The Value of Botox-A Administered as a Single Intra-rectal Injection for the Management of Low Anterior Resection Syndrome: A Phase II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01589471
• Other study ID #: CE 11.088
• Status: Completed
• Phase: Phase 2
• First received: April 27, 2012
• Last updated: February 9, 2018
• Start date: May 2012
• Est. completion date: November 2015

Study information

• Verified date: May 2015
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Low anterior resection syndrome (LARS) is frequent after treatment for low rectal cancer. Increased bowel frequency and urgency with rectal spasms and incontinence have deleterious impacts on quality of life in a third of the cases.

One possible physiopathology hypothesis suggests an ongoing spastic process; different mechanisms have been postulated. These include alteration of normal anorectal sensation with loss of the recto-anal inhibitory reflex (RAIR), decreased rectal compliance and reduced rectal capacity as well as sphincter damage secondary to preoperative chemoradiation therapy or during surgery.

Current available treatments are often ineffective, highlighting the need for more successful management. Botulinum toxin A (BTX-A) is a neurotoxin inhibiting acetylcholine release at the neuromuscular junction. It is currently used for the treatment of various smooth muscle spastic diseases.

The hypothesis of this study is that intra-rectal BTX-A injections could represent a medical treatment alternative for LARS. The goal of this study is to document the effects of intra-rectal BTX-A injections on sphincter function and quality of life of patients with LARS.

Description:

No more information desired

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: November 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 18 years or older

• Aptitude to sign informed consent

• Diagnosis of low anterior resection syndrome (LARS) : More than 12 months after sphincter-preserving surgery for treatment of locally advanced rectal cancer, Mild to moderate underwear soiling, Baseline Wexner score ranging from 0-16 (moderate symptoms, and Patient-reported imperious defecation or Patient-reported incomplete stool evacuation

• Digital rectal exam (by surgeon) demonstrating satisfying anorectal tonus considering prior radical rectal surgery.

• Willingness to complete questionnaires and manometric studies before and after Botox-A administration

• Prior failed medical treatment, at least one attempt (narcotics, loperamide, cholestyramine, fibers)

Exclusion Criteria:

• Inability to sign informed consent

• Counter-indication to Botox-A administration : Allergy to Botox-A or its ingredients (Clostridium botulinum type A neurotoxin complex, human albumin and sodium chloride, Allergy to other forms of botulinum toxin (Dysport, Xeomin or Myobloc, Myasthenia gravis, Eaton-Lambert syndrome, lateral amyotrophic sclerosis or any other neurological disease which might interfere with neuromuscular function

• Prior use of any form of botulinum toxin A, for any indication

• Infection at proposed Botox-A injection site

• Personal or family history of bleeding diathesis

• Pregnancy or breastfeeding

• Severe incontinence (Wexner score = 17 or daily use of diapers)

• Patient taking anticoagulant. ASA ( acetylsalicylic acid) allowed

Related Conditions & MeSH terms

• Low Anterior Resection Syndrome
• Rectal Cancer
• Rectal Neoplasms
• Syndrome

Intervention

Drug:
• intra-rectal Botulinum toxin A injection
intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis

Locations

Country	Name	City	State
Canada	Centre Hospitalier Universitaire de Montréal	Montreal	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)	Allergan

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score		1 month
Primary	Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score		3 months
Secondary	Efficacy of intra-rectal Botox-A injection on anorectal function as documented with a visual scale for tenesmus and completeness of stool evacuation		1 month and 3 months
Secondary	Efficacy of intra-rectal Botox-A injection on quality of life as documented with EORTC-QlQ standardized questionnaires	EORTC-QIQ is a quality of life questionnaire	1 month and 3 months
Secondary	Efficacy of intra-rectal Botox-A injection as documented with a patient medicine calender	patient-filled calender for usage of any medication intended for symptomatic treatment of LARS	1 month
Secondary	Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized anorectal manometry readings		1 month
Secondary	Long term efficacy of intra-rectal Botox-A injection on anorectal function as documented with Wexner score, EORTC-QLQ questionnaire and visual scale		6 months
Secondary	Safety of intra-rectal Botox-A injections as documented with adverse events monitoring		1 month, 3 months and 6 months